$JAGX
Jaguar Health Inc

2022 Q2 Form 10-Q Financial Statement

#000155837022013831 Filed on August 22, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2021 Q4 2021 Q2
Revenue $2.921M $2.080M $385.0K
YoY Change 658.7% -19.38% -87.85%
Cost Of Revenue $456.0K $469.0K $664.0K
YoY Change -31.33% -40.63% -35.6%
Gross Profit $2.465M $1.611M -$279.0K
YoY Change -983.51% -10.0% -113.04%
Gross Profit Margin 84.39% 77.45% -72.47%
Selling, General & Admin $6.493M $6.951M $7.259M
YoY Change -10.55% 37.64% 32.32%
% of Gross Profit 263.41% 431.47%
Research & Development $2.451M $5.482M $3.870M
YoY Change -36.67% 188.53% 175.44%
% of Gross Profit 99.43% 340.29%
Depreciation & Amortization $558.0K $429.0K $431.0K
YoY Change 29.47% -0.23% 0.23%
% of Gross Profit 22.64% 26.63%
Operating Expenses $8.944M $12.43M $11.13M
YoY Change -19.63% 78.64% 61.5%
Operating Profit -$6.479M -$10.82M -$11.58M
YoY Change -44.05% 109.32% 37.03%
Interest Expense $2.536M -$2.747M $2.009M
YoY Change 26.23% 57.87% 319.42%
% of Operating Profit
Other Income/Expense, Net -$1.084M -$749.0K -$17.00K
YoY Change 6276.47% -121.79%
Pretax Income -$9.390M -$14.32M -$14.08M
YoY Change -33.31% 63.26% 52.42%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.390M -$14.31M -$14.08M
YoY Change -33.31% 63.2% 52.42%
Net Earnings / Revenue -321.47% -688.13% -3657.4%
Basic Earnings Per Share -$0.12 -$0.31
Diluted Earnings Per Share -$0.12 -$308.9K -$0.31
COMMON SHARES
Basic Shares Outstanding 79.70M 45.04M
Diluted Shares Outstanding 79.70M 45.04M

Balance Sheet

Concept 2022 Q2 2021 Q4 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.014M $17.05M $21.99M
YoY Change -59.01% 110.77% 628.21%
Cash & Equivalents $9.014M $17.05M $21.99M
Short-Term Investments
Other Short-Term Assets $5.528M $4.339M $14.73M
YoY Change -62.46% 83.86% 545.88%
Inventory $6.745M $4.900M $3.402M
Prepaid Expenses
Receivables $1.549M $1.709M $4.134M
Other Receivables $526.0K $435.0K $40.00K
Total Short-Term Assets $23.36M $28.43M $44.29M
YoY Change -47.26% 59.81% 281.52%
LONG-TERM ASSETS
Property, Plant & Equipment $583.0K $650.0K $666.0K
YoY Change -12.46% -3.99% -4.86%
Goodwill
YoY Change
Intangibles $22.99M $22.65M $23.49M
YoY Change -2.14% -6.93%
Long-Term Investments
YoY Change
Other Assets $1.754M $446.0K $0.00
YoY Change 1015.0% -100.0%
Total Long-Term Assets $26.52M $24.83M $25.25M
YoY Change 5.06% -0.88% -2.79%
TOTAL ASSETS
Total Short-Term Assets $23.36M $28.43M $44.29M
Total Long-Term Assets $26.52M $24.83M $25.25M
Total Assets $49.89M $53.27M $69.54M
YoY Change -28.26% 24.33% 85.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.645M $4.929M $4.918M
YoY Change 14.78% 3.57% -6.15%
Accrued Expenses $8.913M $7.117M $6.383M
YoY Change 39.64% 58.4% 28.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.953M $3.184M $1.145M
YoY Change 594.59% -15.99% -87.22%
Total Short-Term Liabilities $22.90M $15.47M $12.65M
YoY Change 81.01% 17.03% -48.9%
LONG-TERM LIABILITIES
Long-Term Debt $23.36M $25.02M $24.20M
YoY Change -3.46% 101.47% 5948.75%
Other Long-Term Liabilities $868.0K $919.0K $907.0K
YoY Change -4.3%
Total Long-Term Liabilities $24.23M $25.94M $25.10M
YoY Change -3.49% 108.86% 6175.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.90M $15.47M $12.65M
Total Long-Term Liabilities $24.23M $25.94M $25.10M
Total Liabilities $47.13M $41.41M $37.75M
YoY Change 24.83% 61.51% 50.06%
SHAREHOLDERS EQUITY
Retained Earnings -$246.8M -$219.5M -$193.0M
YoY Change 27.88% 31.51%
Common Stock $249.6M $231.1M $224.8M
YoY Change 11.03% 25.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.716M $11.61M $31.79M
YoY Change
Total Liabilities & Shareholders Equity $49.89M $53.27M $69.54M
YoY Change -28.26% 24.33% 85.04%

Cashflow Statement

Concept 2022 Q2 2021 Q4 2021 Q2
OPERATING ACTIVITIES
Net Income -$9.390M -$14.31M -$14.08M
YoY Change -33.31% 63.2% 52.42%
Depreciation, Depletion And Amortization $558.0K $429.0K $431.0K
YoY Change 29.47% -0.23% 0.23%
Cash From Operating Activities -$10.46M -$8.923M -$9.905M
YoY Change 5.57% 119.78% 147.62%
INVESTING ACTIVITIES
Capital Expenditures -$1.258M $0.00 -$6.000K
YoY Change 20866.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.258M $10.48M -$6.000K
YoY Change 20866.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.246M 3.121M 9.573M
YoY Change -66.09% -71.1% 76.62%
NET CHANGE
Cash From Operating Activities -10.46M -8.923M -9.905M
Cash From Investing Activities -1.258M 10.48M -6.000K
Cash From Financing Activities 3.246M 3.121M 9.573M
Net Change In Cash -8.469M 4.676M -338.0K
YoY Change 2405.62% -30.62% -123.8%
FREE CASH FLOW
Cash From Operating Activities -$10.46M -$8.923M -$9.905M
Capital Expenditures -$1.258M $0.00 -$6.000K
Free Cash Flow -$9.199M -$8.923M -$9.899M
YoY Change -7.07% 119.78% 147.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79698822
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45043863
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69105329
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43574385
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9367000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14081000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-27353000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26090000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79698822
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45043863
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69105329
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43574385
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001585608
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
33.33
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
33.33
CY2022Q1 jagx Consecutive Business Days For Maintaining Bid Price Requirement
ConsecutiveBusinessDaysForMaintainingBidPriceRequirement
P30D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36714
dei Entity Registrant Name
EntityRegistrantName
JAGUAR HEALTH, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2956775
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Pine Street, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94104
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
371-8300
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
dei Trading Symbol
TradingSymbol
JAGX
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9014000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17051000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1549000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1709000
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
526000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
435000
CY2022Q2 us-gaap Inventory Net
InventoryNet
6745000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4900000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5528000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4339000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
23362000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
28434000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
583000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
650000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1195000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1084000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
22991000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
22651000
CY2022Q2 us-gaap Other Assets
OtherAssets
1754000
CY2021Q4 us-gaap Other Assets
OtherAssets
446000
CY2022Q2 us-gaap Assets
Assets
49885000
CY2021Q4 us-gaap Assets
Assets
53265000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5645000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4929000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8913000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7117000
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
390000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
240000
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
7953000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3184000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22901000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15471000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
868000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
919000
CY2022Q2 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
7300000
CY2021Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
7800000
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
23359000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25022000
CY2022Q2 us-gaap Liabilities
Liabilities
47128000
CY2021Q4 us-gaap Liabilities
Liabilities
41412000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
249554000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
231100000
CY2022Q2 us-gaap Minority Interest
MinorityInterest
41000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
242000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-246847000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219494000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2757000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11853000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49885000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53265000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
456000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
664000
us-gaap Cost Of Revenue
CostOfRevenue
911000
us-gaap Cost Of Revenue
CostOfRevenue
1247000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2451000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3870000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7396000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6285000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2144000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2191000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4979000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4330000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4349000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5068000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10493000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8477000
jagx Warrants Inducement Expense
WarrantsInducementExpense
1462000
CY2021Q2 jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
9400000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
11965000
us-gaap Costs And Expenses
CostsAndExpenses
23779000
us-gaap Costs And Expenses
CostsAndExpenses
21973000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6479000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11580000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18233000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20348000
CY2022Q2 us-gaap Interest Expense
InterestExpense
2536000
CY2021Q2 us-gaap Interest Expense
InterestExpense
2009000
us-gaap Interest Expense
InterestExpense
7358000
us-gaap Interest Expense
InterestExpense
3909000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2187000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-753000
CY2022Q2 jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
-709000
CY2021Q2 jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
475000
jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
-477000
jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
1074000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1084000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-253000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9390000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14081000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27554000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26090000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-9390000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-14081000
us-gaap Profit Loss
ProfitLoss
-27554000
us-gaap Profit Loss
ProfitLoss
-26090000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-23000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-201000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9367000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14081000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27353000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26090000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79698822
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45043863
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69105329
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43574385
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8109000
CY2022Q2 jagx Stock Issued During Period In Exchange Of Notes Payable And Accrued Interest
StockIssuedDuringPeriodInExchangeOfNotesPayableAndAccruedInterest
467000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
95000
CY2022Q2 jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
5000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1017000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-9390000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2757000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31891000
CY2021Q2 jagx Stock Issued During Period In Exchange Of Notes Payable And Accrued Interest
StockIssuedDuringPeriodInExchangeOfNotesPayableAndAccruedInterest
2982000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1031000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-14081000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31785000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11853000
jagx Stock Issued During Period In Exchange Of Notes Payable And Accrued Interest
StockIssuedDuringPeriodInExchangeOfNotesPayableAndAccruedInterest
4700000
jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
19000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
95000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2080000
us-gaap Profit Loss
ProfitLoss
-27554000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2757000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17202000
jagx Stock Issued During Period In Exchange Of Notes Payable And Accrued Interest
StockIssuedDuringPeriodInExchangeOfNotesPayableAndAccruedInterest
2982000
jagx Stock Issued During Period Value Extinguishment Of Convertible Securities
StockIssuedDuringPeriodValueExtinguishmentOfConvertibleSecurities
2516000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1665000
us-gaap Profit Loss
ProfitLoss
-26090000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31785000
us-gaap Profit Loss
ProfitLoss
-27554000
us-gaap Profit Loss
ProfitLoss
-26090000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6263000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2431000
us-gaap Share Based Compensation
ShareBasedCompensation
2080000
us-gaap Share Based Compensation
ShareBasedCompensation
1667000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2187000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-753000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
984000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
861000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
119000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1000
jagx Adjustment For Shares Issued Upon Exercise Of Restricted Stock Units
AdjustmentForSharesIssuedUponExerciseOfRestrictedStockUnits
95000
jagx Common Stock Issued In Exchange Of Services Rendered
CommonStockIssuedInExchangeOfServicesRendered
19000
jagx Fair Value Adjustment Of Financial Instruments And Hybrid Instrument Designated At Fair Value Of Option
FairValueAdjustmentOfFinancialInstrumentsAndHybridInstrumentDesignatedAtFairValueOfOption
477000
jagx Fair Value Adjustment Of Financial Instruments And Hybrid Instrument Designated At Fair Value Of Option
FairValueAdjustmentOfFinancialInstrumentsAndHybridInstrumentDesignatedAtFairValueOfOption
-1074000
jagx Warrants Issued As Inducement To Exercise Equity Classified Warrants
WarrantsIssuedAsInducementToExerciseEquityClassifiedWarrants
1462000
jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
jagx Derecognition Of Debt Discount
DerecognitionOfDebtDiscount
49000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-160000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-398000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
200000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
12000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1845000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
620000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1190000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1263000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1306000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-37000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
752000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
146000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1885000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2300000
jagx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-124000
jagx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
19000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18152000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16615000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
74000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1184000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1258000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
jagx Repayment Of Insurance Premium Fee Classified As Financing Activity
RepaymentOfInsurancePremiumFeeClassifiedAsFinancingActivity
118000
jagx Repayment Of Insurance Premium Fee Classified As Financing Activity
RepaymentOfInsurancePremiumFeeClassifiedAsFinancingActivity
233000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10975000
jagx Repayment Of Receivables Secured Borrowing
RepaymentOfReceivablesSecuredBorrowing
1822000
jagx Payment Of Equity Line Of Credit Warrant Offering Cost
PaymentOfEquityLineOfCreditWarrantOfferingCost
35000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11396000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40443000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-23000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8037000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23822000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17051000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8090000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9014000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31912000
us-gaap Interest Paid Net
InterestPaidNet
11000
us-gaap Interest Paid Net
InterestPaidNet
8000
jagx Shares Issued In Exchange Of Notes Payable And Accrued Interest
SharesIssuedInExchangeOfNotesPayableAndAccruedInterest
4233000
jagx Shares Issued In Exchange Of Notes Payable And Accrued Interest
SharesIssuedInExchangeOfNotesPayableAndAccruedInterest
2982000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1776000
jagx Umbrella Insurance Financing
UmbrellaInsuranceFinancing
1183000
jagx Reversal Of Deferred Offering Costs
ReversalOfDeferredOfferingCosts
13000
CY2022Q1 jagx Bid Price Requirement Compliance Grace Period
BidPriceRequirementComplianceGracePeriod
P180D
CY2022Q1 jagx Bid Price Requirement Compliance Grace Period
BidPriceRequirementComplianceGracePeriod
P180D
CY2022Q3 us-gaap Share Price
SharePrice
1.00
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-246800000
CY2022Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
7342000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
563451
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2401818
CY2021 jagx Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
168750
CY2021 jagx Class Of Warrant Or Right Exercises
ClassOfWarrantOrRightExercises
-2007117
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its unaudited condensed consolidated financial statements and the accompanying notes. The accounting policies that </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reflect the Company’s more significant estimates and judgments and that the Company believes are the most critical to aid in fully understanding and evaluating its reported financial results are the valuation of stock options, valuation of hybrid instruments designated at fair value option (“FVO”), valuation of warrant liabilities, acquired in-process research and development (“IPR&amp;D”), and useful lives assigned to long-lived assets; impairment assessment of non-financial assets; valuation adjustments for excess and obsolete inventory; allowance for doubtful accounts; deferred taxes and valuation allowances on deferred tax assets; evaluation and measurement of contingencies; and recognition of revenue, including estimates for product returns. Those estimates could change, and as a result, actual results could differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, the World Health Organization declared the COVID-19 outbreak to be a pandemic. During the period ended June 30, 2022, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it. For a discussion of risks of COVID-19 relating to the Company’s business, see “Item 1A. - Risk Factors- Risks Related to Our Business- The novel coronavirus global pandemic could adversely impact our business, including our supply chain, clinical trials and commercialization of Mytesi and Canalevia.”</p>
CY2021Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
1000
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
7819000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2022Q2 us-gaap Inventory Adjustments
InventoryAdjustments
0
CY2021Q4 us-gaap Inventory Adjustments
InventoryAdjustments
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q2 jagx Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
9532000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18191000
CY2021Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2022Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4200
jagx Number Of Contracts
NumberOfContracts
2
CY2022Q2 jagx Number Of Specialty Pharmacies
NumberOfSpecialtyPharmacies
4
jagx Number Of Portfolio Of Contract
NumberOfPortfolioOfContract
1
jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2021Q2 jagx Collaboration Revenue Net
CollaborationRevenueNet
0
jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2022Q2 jagx Collaboration Revenue Net
CollaborationRevenueNet
0
jagx Modifications To Liability Classified Instruments
ModificationsToLiabilityClassifiedInstruments
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modifications to Liability-classified Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accounting for debt modifications and exchange transactions, it is the Company’s policy to first determine whether it qualifies as a troubled debt restructuring (“TDR”) pursuant to the guidance provided in ASC 470-60. A debt modification or exchange transaction that is not within the scope of the ASC 470-60 is accounted for under ASC 470-50 to determine if the transaction is a mere modification or an extinguishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the three and six months ended June 30, 2021, the Company amended the terms of its October 2020 Purchase Agreement and Exchange Note 2, respectively. In the three and six months ended June 30, 2022, the Company entered into another amendment on the terms of its October 2020 Purchase Agreement (see Note 8).</p>
CY2021Q4 us-gaap Sale Of Stock Percentage Of Ownership After Transaction
SaleOfStockPercentageOfOwnershipAfterTransaction
0.99
jagx Modifications To Equity Classified Instruments
ModificationsToEquityClassifiedInstruments
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Modifications to Equity-classified Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accounting for modifications of equity-classified warrants, it is the Company’s policy to determine the impact by analogy to the share-based compensation guidance of ASC 718, <i style="font-style:italic;">Compensation - Stock Compensation </i>(“ASC 718”). The model for a modified share-based payment award that is classified as equity and remains classified in equity after the modification is addressed in ASC 718-20-35-3. Pursuant to that guidance, the incremental fair value from the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">modification is recognized as an expense in the statements of operations to the extent the modified instrument has a higher fair value; however, in certain circumstances, such as when an entire class of warrants is modified, the measured increase in fair value may be more appropriately recorded as a deemed dividend, depending upon the nature of the warrant modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not modify any equity-classified warrants in the three and six months ended June 30, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accounting for amendments to preferred stock, it is the Company’s policy to measure the impact by analogy to ASC 470-50 in determining if such an amendment is an extinguishment or a modification. If the amendment results in an extinguishment, the Company follows the SEC staff guidance in ASC 260-10-S99-2 and ASC 470-20. If the amendment results in a modification, the Company follows the model in either ASC 718 or ASC 470-50, depending on the nature of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not modify any preferred stock in the three and six months ended June 30, 2022 and 2021.</p>
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
563451
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
563451
CY2019Q1 jagx Number Of Promissory Notes Issued
NumberOfPromissoryNotesIssued
21
CY2019Q3 jagx Class Of Warrant Or Right Number Of Securities Exercisable
ClassOfWarrantOrRightNumberOfSecuritiesExercisable
927083
us-gaap Profit Loss
ProfitLoss
-26090000
CY2022Q2 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
7342000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6221000
CY2022Q2 us-gaap Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
1121000
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
1952000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1248000
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
3044000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2760000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1749000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
892000
CY2022Q2 us-gaap Inventory Net
InventoryNet
6745000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4900000
jagx Common Stock Voting Rights Number
CommonStockVotingRightsNumber
1
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1022000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
948000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
439000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
298000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
583000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
650000
CY2022Q2 jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
16000
jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
141000
CY2021Q2 jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
8000
jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
17000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
22991000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
22651000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
422000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
843000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
422000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
844000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
963000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1924000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1924000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1924000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1924000
CY2018Q3 jagx Letter Of Credit Received As Collateral
LetterOfCreditReceivedAsCollateral
475000
CY2018Q3 jagx Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
9580
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
21000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4200
CY2022Q1 jagx Operating Lease Deposits Paid
OperatingLeaseDepositsPaid
9000
CY2022Q1 jagx Operating Lease Deposits Paid
OperatingLeaseDepositsPaid
9500
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1195000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1084000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
390000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
240000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
868000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
919000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1258000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1159000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M7D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M15D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1846
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.2110
us-gaap Operating Lease Payments
OperatingLeasePayments
321000
us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
301000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
463000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
601000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
518000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
566000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
534000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
122000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
89000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1594000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1604000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
336000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
445000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1258000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1159000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
390000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
240000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
868000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
919000
CY2020Q3 jagx Collaboration Agreement Term
CollaborationAgreementTerm
P2Y6M
CY2020Q3 jagx Collaboration Agreement Extension Term
CollaborationAgreementExtensionTerm
P2Y
CY2017Q3 jagx Percentage Of Amount Received To Be Paid To Glenmark
PercentageOfAmountReceivedToBePaidToGlenmark
0.25
CY2017Q3 jagx Maximum Amount To Be Received By Glenmark
MaximumAmountToBeReceivedByGlenmark
7000000.0
jagx Payments Made To Date To Glenmark
PaymentsMadeToDateToGlenmark
1200000
jagx Payments Made To Date To Glenmark
PaymentsMadeToDateToGlenmark
1300000
CY2019Q3 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
2600000
CY2021Q2 us-gaap Unusual Or Infrequent Item Insurance Proceeds
UnusualOrInfrequentItemInsuranceProceeds
0
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-753000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1021165
CY2020Q4 jagx Carrying Amount In Excess Of Fair Value Amount New Instruments
CarryingAmountInExcessOfFairValueAmountNewInstruments
2500000
jagx Schedule Of Common Stock Reserved For Future Issuance
ScheduleOfCommonStockReservedForFutureIssuance
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,319,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,464,803</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inducement options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,289</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options available for grant under stock option plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 697,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 631,270</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock unit awards issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,376,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 487,456</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 563,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 563,451</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,074,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,185,269</p></td></tr></table>
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2319718
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2464803
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
697974
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
631270
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3376086
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
487456
CY2022Q2 jagx Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued And Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuedAndOutstandingNumber
563451
CY2021Q4 jagx Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued And Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuedAndOutstandingNumber
563451
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7074762
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4185269
CY2021Q4 us-gaap Minority Interest
MinorityInterest
242000
CY2022Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
23000
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
201000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
10 years
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2888630
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.06
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
418094
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
695995
jagx Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValueAmount
4.16
jagx Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValueAmount
4.16
jagx Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValueAmount
4.49
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-9390000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-14081000
us-gaap Profit Loss
ProfitLoss
-27554000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1017000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1031000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2080000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1667000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.640
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.032
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9367000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14081000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27353000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26090000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79698822
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45043863
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69105329
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43574385
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6390641
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3553999
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32746090
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2022Q2 us-gaap Investments
Investments
29232000
CY2021Q4 us-gaap Investments
Investments
29232000
CY2022Q2 jagx Loans Receivable Asset
LoansReceivableAsset
83780000
CY2021Q4 jagx Loans Receivable Asset
LoansReceivableAsset
75333000
CY2022Q2 us-gaap Assets
Assets
49885000
CY2021Q4 us-gaap Assets
Assets
53265000

Files In Submission

Name View Source Status
0001558370-22-013831-index-headers.html Edgar Link pending
0001558370-22-013831-index.html Edgar Link pending
0001558370-22-013831.txt Edgar Link pending
0001558370-22-013831-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jagx-20220630.xsd Edgar Link pending
jagx-20220630x10q.htm Edgar Link pending
jagx-20220630xex31d1.htm Edgar Link pending
jagx-20220630xex31d2.htm Edgar Link pending
jagx-20220630xex32d1.htm Edgar Link pending
jagx-20220630xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jagx-20220630_def.xml Edgar Link unprocessable
jagx-20220630_cal.xml Edgar Link unprocessable
jagx-20220630_lab.xml Edgar Link unprocessable
jagx-20220630_pre.xml Edgar Link unprocessable
jagx-20220630x10q_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending